Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Michael Brody who wrote (923)	6/28/1999 8:29:00 PM
From: StockMiser	Read Replies (1) \| Respond to of 2344

Depends on how you look at it... IMCL has a market cap over 500 million now, but up until the recent analyst coverage and press, it was less than 200 million. BIOM has a market cap around 160 million, which may seem a lot less, but it is actually in the top 4 of all small cap biotechs in late stage cancer treatment trials. It's actually remarkable given this is a Canadian company. Another downside is the float - only TCLN has a bigger float. My point is...IMCL is a bit inflated (but I don't shout about that too loud as it's one of my longterm holdings as well). But IMCL does have the big analyst coverage, institutional accumulation, and a more diverse pipeline - it also has momentum, which has allowed it to exceed it's peers. Comparable companies in market cap: APHT - 157 mil. (has 2 P3 trials for Gastrimune) ILXO - 128 mil. (has 2 products in P3, 1 already fast-tracked) LKST - 148 mil. (1 product in P3) There are at least (8)other small biotechs, also on Phase 3 trials for cancer treatments, all with less than a 100 mil. cap. The good news, imho, is that BIOM can become just as popular as IMCL given the right news and coverage. And you are right about BIOM's vaccines - they do stir the imagination - and they are "real" vaccines with longterm memory and effectiveness (unlike monoclonal antibodies, which are short term only). I think that part of it is timing. Insitutions and analysts want to see full enrollment of P3, and perhaps even the first 6 month data set. If that is followed through with a fast track designation, I think we could see a 500 million cap fairly quick (that's about $10-12/share, and would be equivalent to IMCL). IMCL does have 2 lead products, but the inital marketability of them compared to Theratope is about the same ($150 - 500 million). I sold 3/4 of my position on the ASCO news...but I'm almost back to a full holding. Been buying back on those 3 1/2 - 3 9/16 dips. SM